These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 17093464)

  • 1. Rainbow biotech--South Africa's emerging sector.
    Louët S
    Nat Biotechnol; 2006 Nov; 24(11):1313-6. PubMed ID: 17093464
    [No Abstract]   [Full Text] [Related]  

  • 2. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 3. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 4. Realizing potential: the state of Asian bioentrepreneurship.
    Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 6. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 7. Enthusiasm cools in Q2.
    Lawrence S
    Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
    [No Abstract]   [Full Text] [Related]  

  • 8. Germany biotech gets second chance.
    Sheridan C
    Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 10. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 12. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 13. Japanese giants renew interest in industrial biotech.
    Sipp D
    Nat Biotechnol; 2005 Mar; 23(3):275-6. PubMed ID: 15765071
    [No Abstract]   [Full Text] [Related]  

  • 14. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 15. The responsibilities of growing up.
    Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362
    [No Abstract]   [Full Text] [Related]  

  • 16. 2019 biotech IPOs: party on.
    Morrison C
    Nat Rev Drug Discov; 2020 Jan; 19(1):6-9. PubMed ID: 31907435
    [No Abstract]   [Full Text] [Related]  

  • 17. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

  • 18. Invention and commercialization in optical bioimaging.
    Farkas DL
    Nat Biotechnol; 2003 Nov; 21(11):1269-71. PubMed ID: 14595349
    [No Abstract]   [Full Text] [Related]  

  • 19. Public biotech 2006 - the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
    [No Abstract]   [Full Text] [Related]  

  • 20. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.